Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) submitted a Biologics License Application (BLA) to the FDA on Dec 15, 2025 for imsidolimab to treat generalized pustular psoriasis (GPP).
The BLA is supported by positive global Phase 3 GEMINI-1 and GEMINI-2 results: a single intravenous dose produced rapid clearance (clear or almost clear skin) with efficacy maintained during an approximately 2-year maintenance period with monthly dosing, and a favorable safety profile with no clinically meaningful safety signals reported. Vanda requested priority review, which could enable FDA action as early as mid-2026 if granted.
Positive
- BLA submission to FDA for imsidolimab (Dec 15, 2025)
- Phase 3 GEMINI-1/2 showed rapid skin clearance after single IV dose
- Efficacy maintained through an ~2-year maintenance period with monthly dosing
- Favorable safety profile with no clinically meaningful safety signals
- Priority review requested; potential FDA decision as early as mid-2026
Negative
- Regulatory approval is pending; imsidolimab is not yet approved by FDA
- Small, variable patient population (~2–124 cases per million) limits addressable market size
News Market Reaction – ANAB
In the Dec 15 session, ANAB gained 1.38%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conferences | Neutral | +1.6% | Announced CEO participation in multiple December healthcare investor conferences. |
| Nov 21 | Buyback expansion | Positive | +5.2% | Expanded stock repurchase plan by $100.0 million with strong cash position guidance. |
| Nov 21 | Litigation update | Neutral | +5.2% | Initiated litigation against Tesaro, a GSK subsidiary; limited detail in summary. |
| Nov 10 | Trial failure | Negative | -14.3% | Phase 2 rosnilimab UC trial failed primary and key secondary endpoints; program halted. |
| Nov 04 | Investor conferences | Neutral | -3.6% | Outlined participation in several November healthcare conferences with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across recent events, ANAB’s share price generally aligned with news tone, particularly selling off sharply on negative clinical data and rising on capital return announcements.
Over the past months, ANAB has combined strategic, financial, and clinical catalysts. A $100 million stock repurchase plan and exploration of a business separation followed stronger Q3 results with $76.3 million collaboration revenue and $15.1 million net income. Conversely, a Phase 2 failure in ulcerative colitis on Nov 10, 2025 drove a -14.3% move. Conference participation and litigation updates had more modest effects. Today’s rare-disease BLA submission fits the broader immunology and royalties-focused strategy highlighted in recent filings.
Key Terms
biologics license application regulatory
fda regulatory
igg4 medical
il-36 receptor antagonist medical
orphan disease regulatory
priority review regulatory
autoinflammatory medical
multiple sclerosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The BLA is supported by positive results from the global Phase 3 GEMINI-1 and GEMINI-2 studies, where a single intravenous dose of imsidolimab led to rapid disease clearance, achieving clear or almost clear skin, with efficacy maintained throughout an approximately 2-year maintenance study period with monthly doses. Imsidolimab demonstrated a favorable safety profile with no clinically meaningful safety signals.
GPP is a rare, chronic, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms such as fever and fatigue. Driven primarily by loss-of-function mutations in IL36RN, GPP represents a significant unmet medical need, with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide (e.g., lower in
"The submission of the BLA for imsidolimab marks a critical milestone in our efforts to bring this innovative therapy to patients suffering from GPP," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals. "Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio, including Ponvory®, which is approved for the treatment of relapsing forms of multiple sclerosis and is in clinical development for the treatment of psoriasis and ulcerative colitis. We look forward to potential FDA approval and leveraging our commercial infrastructure to address this debilitating condition."
Vanda has requested priority review for the BLA, citing GPP's status as a rare orphan disease with significant unmet need. If granted, priority review would establish a six-month review cycle, with a potential FDA approval of imsidolimab for the treatment of GPP as early as mid-2026.
References:
- Prinz, J. C. et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. Journal of the European Academy of Dermatology and Venereology 37, 256–273 (2022).
- Marrakchi, S. et al. Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis. New England Journal of Medicine 365, 620–628 (2011).
- Sugiura, K. et al. The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist. Journal of Investigative Dermatology 133, 2514–2521 (2013).
- Sachen, K. L., Arnold Greving, C. N. & Towne, J. E. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine 156, 155897 (2022).
About GEMINI-1 and GEMINI-2 Studies
In the 45-patient GEMINI-1 Phase 3 trial, patients were randomized 1:1:1 to a single intravenous infusion of 750 mg imsidolimab, 300 mg imsidolimab, or placebo on Day 0. At Week 4 (primary endpoint),
Responders from GEMINI-1 were re-randomized in GEMINI-2 to monthly subcutaneous maintenance dosing with 200 mg imsidolimab or placebo, followed for up to 116 weeks. All patients on active maintenance therapy maintained clear or almost clear skin with no flares, compared to
About Imsidolimab and GPP
Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).
GPP flares involve painful pustules over large skin areas, accompanied by redness, itching, and systemic symptoms, and can be life-threatening if untreated.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, but not limited to statements regarding the estimated prevalence of GPP, the potential for FDA approval of the imsidolimab BLA, the commercial availability of imsidolimab to treat patients with GPP, the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, and the potential timing of FDA approval of imsidolimab for the treatment of GPP, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the accuracy of the estimates of the number of patients with GPP worldwide, Vanda's ability to obtain regulatory approval of, and successfully commercialize, imsidolimab for the treatment of GPP, Vanda's ability to satisfy the conditions necessary to extend imsidolimab's regulatory and patent exclusivity into the late 2030s and the FDA's determination that the BLA and its supporting documentation meet the criteria for priority review. Therefore, no assurance can be given that the results or developments anticipated by Vanad will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html
SOURCE Vanda Pharmaceuticals Inc.